Liscolin-P Tablet is a combination pharmaceutical formulation containing Citicoline 500mg and Piracetam 400mg, designed to enhance cognitive function and support neurological health. Citicoline, a neuroprotective agent, plays a crucial role in the synthesis of phosphatidylcholine, a major component of neuronal membranes, thereby promoting membrane repair and improving cerebral metabolism. It also facilitates the restoration of neurotransmitter levels, including acetylcholine, which is vital for memory and learning processes. Piracetam, a nootropic agent, modulates neuronal excitability and enhances synaptic plasticity, contributing to improved cognitive performance, memory, and attention. The synergistic action of Citicoline and Piracetam in Liscolin-P Tablet is beneficial in managing cognitive impairments associated with cerebrovascular diseases, traumatic brain injury, and neurodegenerative disorders such as Alzheimer's disease. Additionally, this combination may aid in the treatment of dyslexia, vertigo, and other conditions involving cognitive decline. Liscolin-P is generally well-tolerated, with minimal adverse effects reported. It should be administered under medical supervision, with dosage adjusted according to the patient's clinical condition. Contraindications include hypersensitivity to any component of the formulation. Regular monitoring and adherence to prescribed therapy ensure optimal therapeutic outcomes.